Novan (NASDAQ:NOVN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.53) by 26.42 percent. This is a 457.14 percent decrease over losses of $(0.07) per share from the same period last year.
Akebia Therapeutics Received Interim Response From The FDA To Appeal For Vadadustat For The Treatment Of Anemia Due To Chronic Kidney Disease
Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company received a second interim
